Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by tonyxdsunon Nov 15, 2009 12:14am
202 Views
Post# 16487902

RE: RE: RE: RE: RE: RE: RE: RE: Karead, you are mi

RE: RE: RE: RE: RE: RE: RE: RE: Karead, you are mistock price is nothing to do with the company's current/history, but it's future.
0
for 2007, the future is 2008 which was bright.  for 2009, the future looks dark. 



----
 just finished listening to HEM's conference call, and I have reviewed their Q3 financials. I too am comfortable holding this stock. Happy, obviously not. Optimistic, very. In my opinion, the current share price represents a buying opportunity. For those who bought in around .85/share, congratulations. You are going to make money; the question is, how much? I have no doubt you'll make 15-20% between now and the end of the year. After that, you're on your own:-) That's my prediction, but in this game, don't take it too seriously. I could be wrong, but here's why I think I'm right:

 

Their loss per share is pretty much the same as it was for Q3 2007, but their share price in November 2007 was 2.5-3.0 times higher than Friday's close of .85/share. Although they have $1.7MM less in cash than they did at this time in '07, they also have $3.5MM less in Current Liabilities. Strong balance sheet. They also have more on the go in 2009 than they did in 2007, including inroads into Europe (e.g. agreement with CLAAS), and hopefully in the not too distant future, similar progress in China; longer term, India. Their international sales will gain a boost due to a weaker US $. Which I think will be weak for at least the next 12-18 months. Their debt is 70% of GDP, and the printing press is running 24x7.

 

I will be resuming a strategy of accumulating shares here and there while it continues to trade at < $1.

 

On the speculative side, there's always room for a big announcement, or better yet, a blurb on Cramer's Mad Money show;-)

 

Good luck to all longs.

Bullboard Posts